News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

July

12

electroCore Provides Select Second Quarter 2022 Financial Guidance

Record revenue will be at least $2.1 million; approximately 65% growth over second quarter 2021 June...

24

Non-Invasive Vagus Nerve Stimulation (nVNS) Enters New Stage of COVID-19 Research

electroCore and the Hospital Clínico Universitario de Valencia have completed patient enrollment in SAVIOR-1 study ROCKAWAY,...

11

electroCore Announces Completion of Enrollment in SAVIOR-1 Study of Non-Invasive Vagus Nerve Stimulation (nVNS) in COVID-19 Patients Exhibiting Respiratory Symptoms

Spain-based study has enrolled 110 patients over 18 years of age with respiratory failure...

13

electroCore Announces Second Quarter Financial Results

Received EUA and initiated gammaCore Sapphire CV distribution process for certain known or suspected...

13

electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

Intended use allows gammaCore Sapphire CV use at home or in a healthcare setting...

14

electroCore Announces First Quarter Financial Results

Generated first quarter revenue of $734,000 Secured FDA clearance of gammaCore™ (nVNS) label expansion for migraine...

29

electroCore Provides Update on COVID-19 Clinical Initiatives

Randomized controlled investigator-initiated trial (IIT) of non-invasive vagus nerve stimulation (nVNS) therapy currently enrolling...

Recent developments

News

July

12

electroCore Provides Select Second Quarter 2022 Financial Guidance

February

24

Non-Invasive Vagus Nerve Stimulation (nVNS) Enters New Stage of COVID-19 Research

February

11

electroCore Announces Completion of Enrollment in SAVIOR-1 Study of Non-Invasive Vagus Nerve Stimulation (nVNS) in COVID-19 Patients Exhibiting Respiratory Symptoms

August

13

electroCore Announces Second Quarter Financial Results

July

13

electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

May

14

electroCore Announces First Quarter Financial Results

April

29

electroCore Provides Update on COVID-19 Clinical Initiatives